EUVIMEDEUVIMED entdecken
Crossref

Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma

Yi Fan Chen iD, Arshna Qureshi, Jessica E Sigel, Navid Sadri iD

Am J Clin Pathol · 2025

DOI: 10.1093/ajcp/aqaf122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Am J Clin Pathol, 2025. Verfasst von Yi Fan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Skin Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

BRAF V600E/K mutations are significant drivers of metastatic melanoma, and therapies that selectively target these mutations have significantly improved patient long-term survival. Emerging evidence suggests that tumors harboring BRAF non-V600E/K mutations are susceptible to MEK-targeting therapies, but these mutations are not always assessed in clinical workup. To assess whether patient stratification for targeted therapy can be improved, we characterized the prevalence and nature of BRAF non-V600E/K mutations in a cohort of patients diagnosed with metastatic melanoma.

Methods

We extracted DNA from 99 specimens collected between June 2019 and September 2021. The samples were analyzed using next-generation sequencing to identify mutations in BRAF exon 15 and to assess their susceptibility to targeted therapies.

Results

Eleven percent of patient specimens contained BRAF non-V600E/K mutations in exon 15. Of the mutations identified, all have prior evidence of susceptibility to targeted MEK therapies. Among those patients, less than half received targeted MEK therapies.

Conclusions

Next-generation sequencing is a sensitive platform for profiling BRAF exon 15 mutations that cannot be detected by other techniques. Our results support the routine sequencing of BRAF exon 15 to improve patient stratification for therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafSkin NeoplasmsHumansExonsFemaleMaleHigh-Throughput Nucleotide SequencingMutationMiddle AgedAgedAdultAged, 80 and overDNA Mutational Analysis

Stichwörter der Autor:innen

DNA mutational analysishigh-throughput nucleotide sequencingmelanomamolecular targeted therapyprecision medicineproto-oncogene proteins B-raf

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.
  • Medical Scientist Training Program, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
  • Department of Pathology, Kaiser Permanente Oakland Medical Center, Oakland, CA, United States.

ORCID-Profile: Yi Fan Chen, Navid Sadri

Zitieren

APA

Chen, Y. F., Qureshi, A., Sigel, J. E., & Sadri, N. (2025). Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaf122

Vancouver

Chen YF, Qureshi A, Sigel JE, Sadri N. Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma. Am J Clin Pathol. 2025. doi:10.1093/ajcp/aqaf122

BibTeX
@article{Chen2025,
  author = {Chen, Yi Fan and Qureshi, Arshna and Sigel, Jessica E and Sadri, Navid},
  title = {Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma},
  journal = {Am J Clin Pathol},
  year = {2025},
  doi = {10.1093/ajcp/aqaf122}
}
Kostenlos starten →